Small molecule inhibitors of α-synuclein filament assembly

Biochemistry

Volumn 45, Issue 19, 2006, Pages 6085-6094

  Masuda, Masami ^a,b   Suzuki, Nobuyuki ^c   Taniguchi, Sayuri ^a,d   Oikawa, Takayuki ^a,b   Nonaka, Takashi ^a   Iwatsubo, Takeshi ^d   Hisanaga, Shin Ichi ^b   Goedert, Michel ^e   Hasegawa, Masato ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO METROPOLITAN UNIVERSITY   (Japan)

^c DAIICHI SANKYO CO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL FUELS; BIOCHEMISTRY; CELLS; DISEASE CONTROL; ENZYME INHIBITION; OLIGOMERS;

FILAMENT ASSEMBLIES; INHIBITORY COMPOUNDS; LOW MICROMOLAR RANGE;

MOLECULES;

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTHRACYCLINE; APIGENIN; BAICALEIN; CATECHIN; CONGO RED; CURCUMIN; DAIDZEIN; DELPHINIDIN; DOPAMINE; EPICATECHIN; EPICATECHIN GALLATE; EXIFONE; GINGEROL; GOSSYPETIN; HINOKIFLAVONE; LUTEOLIN; MACROLIDE; MYRICETIN; NARINGENIN; PHENOTHIAZINE DERIVATIVE; POLYPHENOL DERIVATIVE; PORPHYRIN DERIVATIVE; QUERCETIN; RIFAMYCIN; RUTOSIDE; TAU PROTEIN; TERPENOID; UNINDEXED DRUG;

ALPHA SYNUCLEINOPATHY; AMYLOIDOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ASSEMBLY;

ALPHA-SYNUCLEIN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; NEUROBLASTOMA;

EID: 33646570598     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0600749     Document Type: Article

References (77)

1. Goedert, M. (2001) α-Synuclein and neurodegenerative diseases, Nat. Rev. Neurosci. 2, 492-501.
2. Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) α-Synuclein in Lewy bodies, Nature 388, 839-840.
3. Baba, M., Nakajo, S., Tu, P.-H., Tomita, T., Nakaya, K., Lee, V. M.-Y., Trojanowski, J. Q., and Iwatsubo, T. (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am. J. Pathol. 152, 879-884.
4. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies, Proc. Natl. Acad. Sci. U.S.A. 95, 6469-6473.
5. Wakabayashi, K., Yoshimoto, M., Tsuji, S., and Takahashi, H. (1998) α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy, Neurosci. Lett. 249, 180-182.
6. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., and Goedert, M. (1998) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, Neurosci. Lett. 251, 205-208.
7. Tu, P. H., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., and Trojanowski, J. Q. (1988) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein, Ann. Neurol. 44, 415-422.
8. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell Biol. 4, 160-164.
9. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease, Science 276, 2045-2047.
10. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease, Nat. Genet. 18, 106-108.
11. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia, Ann. Neurol. 55, 164-173.
12. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) α-Synuclein locus triplication causes Parkinson's disease, Science 302, 841.
13. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Lavor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebre, L., Amouyel, P., Farreer, M., and Destée, A. (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease, Lancet 364, 1167-1169.
14. Ibanez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Pollak, P., Agid, Y., Dürr, A., and Brice, A. (2004) Causal relation between α-synuclein gene duplication and familial Parkinson's disease, Lancet 364, 1169-1171.
15. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A. 90, 11282-11286.
16. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain, FEBS Lett. 345, 27-32.
17. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., and Lansbury, P. T. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry 35, 13709-13715.
18. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes, J. Biol. Chem. 273, 9443-9449.
19. Jensen, P. H., Nielsen, M. H., Jakes, R., Dotti, C. G., and Goedert, M. (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation, J. Biol. Chem. 273, 26292-26294.
20. Jo, E., McLaurin, J. A., Yip, C. M., St George-Hyslop, P., and Fraser, P. E. (2000) α-Synuclein membrane interactions and lipid specificity, J. Biol. Chem. 275, 34328-34334.
21. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2000) Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis, J. Biol. Chem. 275, 34393-34398.
22. Eliezer, D., Kutluay, E., Bussell, R., and Browne, G. (2001) Conformational properties of α-synuclein in its free and lipid-associated states, J. Mol. Biol. 307, 1061-1073.
23. Chandra, S., Chen, X., Rizo, J., Jahn, R., and Südhof, T. (2003) A broken α-helix in folded α-synuclein, J. Biol. Chem. 278, 15313-15318.
24. Jao, C. C., Der-Sarkissian, A., Chen, J., and Langen, R. (2004) Structure of membrane-bound α-synuclein studied by site-directed spin labeling, Proc. Natl. Acad. Sci. U.S.A. 101, 8331-8336.
25. Ulmer, T. S., Bax, A., Cole, N. B., and Nussbaum, R. L. (2005) Structure and dynamics of micelle-bound human α-synuclein, J. Biol. Chem. 280, 9595-9603.
26. Crowther, R. A., Jakes, R., Spillantini, M. G., and Goedert, M. (1998) Synthetic filaments assembled from C-terminally truncated α-synuclein, FEBS Lett. 436, 309-312.
27. El-Agnaf, O. M. A., Jakes, R., Curran, M. D., and Wallace, A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease, FEBS Lett. 440, 67-70.
28. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease, Nat. Med. 4, 1318-1320.
29. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., and Crowther, R. A. (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation, Proc. Natl. Acad. Sci. U.S.A. 97, 4897-4902.
30. Miake, H., Mizusawa, H., Iwatsubo, T., and Hasegawa, M. (2002) Biochemical characterization of the core structure of α-synuclein filaments, J. Biol. Chem. 277, 19213-19219.
31. Der-Sarkissian, A., Jao, C. J., Chen, J., and Langen, R. (2003) Structural organization of α-synuclein fibrils studied by site-directed spin labeling, J. Biol. Chem. 278, 37530-37535.
32. Murray, I. V., Giasson, B. I., Quinn, S. M., Koppaka, V., Axelsen, P. H., Ischiropoulos, H., Trojanowski, J. Q., and Lee, V. M.-Y. (2003) Role of α-synuclein carboxy-terminus on fibril formation in vitro, Biochemistry 42, 8530-8540.
33. Dedmon, M. K., Lindorff-Larsen, K., Christodoulou, J., Vendruscolo, M., and Dobson, C. M. (2005) Mapping long-range interactions in α-synuclein using spin-label NMR and ensemble molecular dynamics simulations, J. Am. Chem. Soc. 127, 476-477.
34. Bertoncini, C. W., Jung, Y.-S., Fernandez, C. O., Hoyer, W., Griesinger, C., Jovin, T. M., and Zweckstetter, M. (2005) Structural characterization of copper(II) binding to α-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease, Proc. Natl. Acad. Sci. U.S.A. 102, 1430-1435.
35. Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Crowther, R. A., and Goedert, M. (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human α-synuclein, FEBS Lett. 576, 363-368.
36. Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., and Giasson, B. I. (2005) The E46K mutation in α-synuclein increases amyloid fibril formation, J. Biol. Chem. 280, 7800-7807.
37. Giasson, B. I., Uryu, K., Trojanowski, J. Q., and Lee, V. M.-Y. (1999) Mutant and wild-type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro, J. Biol. Chem. 274, 7619-7622.
38. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., Louis, J. C., Wypych, J., Biere, A. L., and Citron, M. (1999) Both familial Parkinson' s disease mutations accelerate α-synuclein aggregation, J. Biol. Chem. 274, 9843-9846.
39. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein, Biochemistry 40, 11604-11613.
40. Conway, K. A., Lee, S.-J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy, Proc. Natl. Acad. Sci. U.S.A. 97, 571-576.
41. Goedert, M., Spillantini, M. G., and Davies, S. W. (1998) Filamentous nerve cell inclusions in neurodegenerative diseases, Curr. Opin. Neurobiol. 8, 619-632.
42. Prusiner, S. B. (2001) Shattuck lecture: Neurodegenerative diseases and prions, N. Engl. J. Med. 344, 1516-1526.
43. Findeis, M. A. (2000) Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization, Biochim. Biophys. Acta 1502, 76-84.
44. Cashman, N. R., and Caughey, B. (2004) Prion diseases: Close to effective therapy? Nat. Rev. Drug Discovery 3, 874-884.
45. Heiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., Herhaus, C., Barnickel, G., Böttcher, H., Lehrach, H., and Wanker, E. E. (2002) Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay, Proc. Natl. Acad. Sci. U.S.A. 99, 16400-16406.
46. Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E. M., Biernat, J., and Mandelkow, E. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells, J. Biol. Chem. 280, 3628-3635.
47. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S.-I., Iwatsubo, T., Goedert, M., and Hasegawa, M. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins, J. Biol. Chem. 280, 7614-7623.
48. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T. (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct, Science 294, 1346-1349.
49. Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., and Lee, V. M.-Y. (2005) Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations, J. Biol. Chem. 280, 21212-21219.
50. Cappai, R., Leek, S.-L., Tew, D. J., Williamson, N. A., Smith, D. P., Galatis, D., Sharples, R. A., Curtain, C. C., Ali, F. E., Cherny, R. A., Culvenor, J. G., Bottomley, S. P., Masters, C. L., Barnham, K. J., and Hill, A. F. (2005) Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway, FASEB J. 19, 1377-1379.
51. Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F., and Fink, A. L. (2004) The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils, J. Biol. Chem. 279, 26846-26857.
52. Lee, E.-N., Cho, H.-J., Lee, C.-H., Lee, D., Chung, K. C., and Paik, S. R. (2004) Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of α-synuclein, Biochemistry 43, 3704-3715.
53. Li, J., Zhu, M., Rajamani, S., Uversky, V. N., and Fink, A. L. (2004) Rifampicin inhibits α-synuclein fibrillation and disaggregates fibrils, Chem. Biol. 11, 1513-1521.
54. Nonaka, T., Iwatsubo, T., and Hasegawa, M. (2005) Ubiquitination of α-synuclein, Biochemistry 44, 361-368.
55. Masuda, M., Dohmae, N., Nonaka, T., Oikawa, T., Hisanaga, S. I., Goedert, M., and Hasegawa, M. (2006) Cysteine misincorporation in bacterially expressed human α-synuclein, FEBS Lett. 580, 1775-1779.
56. Naiki, H., and Nakakuki, K. (1996) First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro, Lab. Invest. 74, 374-383.
57. Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., and Crowther, R. A. (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease, Neuron 3, 519-526.
58. Hasegawa, M., Smith, M. J., and Goedert, M. (1998) Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly, FEBS Lett. 437, 207-210.
59. Ding, T. T., Lee, S.-J., Rochet, J. C., and Lansbury, P. T. (2002) Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes, Biochemistry 41, 10209-10217.
60. Mandel, S., and Youdim, B. H. (2004) Catechin polyphenols: Neurodegeneration and neuroprotection in neurodegenerative diseases, Free Radical Biol. Med. 37, 304-317.
61. Lorenzo, A., and Yankner, B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by congo red, Proc. Natl. Acad. Sci. U.S.A. 91, 12243-12247.
62. Esler, W. P., Stimson, E. R., Ghilardi, J. R., Felix, A. M., Lu, Y.-A., Vinters, H. V., Mantyh, P. W., and Maggio, J. E. (1997) Aβ deposition inhibitor screen using synthetic amyloid, Nat. Biotechnol. 15, 258-263.
63. Caughey, B., and Race, R. E. (1992) Potent inhibition of scrapie-associated PrP accumulation by congo red, J. Neurochem. 59, 768-771.
64. Caughey, B., Ernest, D., and Race, R. E. (1993) Congo red inhibition of scrapie agent replication, J. Virol. 67, 6270-6272.
65. Heiser, V., Scherzinger, E., Boeddrich, A., Nordhoff, E., Lurz, R., Schugardt, N., Lehrach, H., and Wanker, E. E. (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy, Proc. Natl. Acad. Sci. U.S.A. 97, 6739-6744.
66. Sánchez, I., Mahlke, C., and Yuan, J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders, Nature 421, 373-379.
67. Skovronsky, D. M., Zhang, B., Kung, M.-P., Kung, H. F., Trojanowski, J. Q., and Lee, V. M.-Y. (2000) In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U.S.A. 97, 7609-7614.
68. 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques, Eur. J. Med. Chem. 39, 573-578.
69. 1H MRI detection of amyloid β plaques in vivo, Nat. Neurosci. 8, 527-533.
70. Schmidt, M. L., Schuck, T., Sheridan, S., Kung, M.-P., Kung, H., Zhuang, Z.-P., Bergeron, C., Lamarche, J. S., Skovronsky, D., Giasson, B. I., Lee, V. M.-Y., and Trojanowski, J. Q. (2001) The fluorescent Congo red derivative, (trans,trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse β-pleated sheet structures in postmortem human neurodegenerative disease brains, Am. J. Pathol. 159, 937-943.
71. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300, 486-489.
72. Emadi, S., Liu, R., Yuan, B., Schulz, P., McAllister, C., Lyubchenko, Y., Messer, A., and Sierks, M. R. (2004) Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity, Biochemistry 43, 2871-2878.
73. Dedmon, M. W., Christodoulou, J., Wilson, M. R., and Dobson, C. M. (2005) Heat shock protein 70 inhibits α-synuclein fibril formation via preferential binding to prefibrillar species, J. Biol. Chem. 280, 14733-14740.
74. El-Agnaf, O. M. A., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., and Wallace, D. (1998) Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments, FEBS Lett. 440, 71-75.
75. Volles, M. J., and Lansbury, P. T. (2003) Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease, Biochemistry 42, 7871-7878.
76. Giasson, B. I., and Lee, V. M.-Y. (2003) Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8.
77. Chen, L., and Feany, M. B. (2005) α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease, Nat. Neurosci. 8, 657-663.